Breaking News Instant updates and real-time market news.

AMGN

Amgen

$167.50

0.6 (0.36%)

09:12
10/10/16
10/10
09:12
10/10/16
09:12

Amgen: Analyses confirm Vectibix provides survival benefit over chemotherapy

Amgen announced results from new retrospective analyses of key studies with Vectibix in metastatic colorectal cancer patients. The retrospective analysis of the PEAK study in mCRC patients with RAS wild-type primary tumors of left-sided origin showed that patients receiving Vectibix plus FOLFOX6 as first-line treatment achieved 43.4 months median overall survival, an increase of 11.4 months when compared to FOLFOX6 plus bevacizumab. Additionally, for this patient population, the retrospective analysis of the PRIME study showed Vectibix plus FOLFOX4 increased OS by 6.7 months when compared to FOLFOX4 alone. These data were presented today at the European Society for Medical Oncology 2016 Congress in Copenhagen. The PEAK and PRIME retrospective analyses, respectively, also showed that mCRC patients with RAS wild-type tumors of left-sided origin receiving Vectibix plus FOLFOX chemotherapy achieved median progression-free survival of 14.6 months, an increase of 3.1 months when compared to FOLFOX plus bevacizumab, and 12.9 months, an increase of 3.7 months when compared to FOLFOX chemotherapy alone. The retrospective analyses found that approximately 80% of tumors originate in the left side of the colon. Additionally, tumors originating in the right side of the colon are currently associated with a poorer prognosis than tumors originating in the left side of the colon. In patients with RAS wild-type mCRC with tumors originating on the right side, a subgroup of patients responded to Vectibix and chemotherapy, achieving numerically higher response rates over chemotherapy with or without bevacizumab. However, no final conclusions can be made regarding the ability to differentiate treatment regimens for patients with right-sided tumors. The safety profile of the use of Vectibix in combination with FOLFOX-based chemotherapy in mCRC has been previously reported. The aggregate safety data is unchanged by this retrospective analysis of outcomes based on CRC tumor site of origin.

  • 05

    Nov

  • 06

    Nov

  • 19

    Jul

AMGN Amgen
$167.50

0.6 (0.36%)

09/01/16
09/01/16
NO CHANGE

Amgen's sBLA for Blincyto approved by FDA
Amgen's supplemental Biologics License Application for Blincyto has been approved by the FDA to include new data supporting the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This indication is approved under accelerated approval, and continued approval may be contingent upon verification of clinical benefit in subsequent trials. The approval is based on results from the Phase 1/2 '205, an open-label, multicenter, single-arm trial, which evaluated the efficacy and safety of BLINCYTO in pediatric patients with relapsed or refractory B-cell precursor ALL. Blincyto was granted breakthrough therapy, priority review and orphan drug designations by FDA, and is now approved in the U.S. for the treatment of Ph- relapsed or refractory B-cell precursor ALL. In November 2015, BLINCYTO was granted conditional marketing authorization in the European Union for the treatment of adults with Ph- relapsed or refractory B-cell precursor ALL.
09/27/16
GSCO
09/27/16
NO CHANGE
Target $206
GSCO
Conviction Buy
Goldman surprised by Amgen's Kyprolis outcome in first-line multiple myeloma
Last night, Amgen announced Phase 3 Kypolis CLARION study did not meet the primary endpoint in first-line multiple myeloma. Goldman analyst Terence Flynn was surprised by this outcome given the prior positive superiority data for Kyprolis versus Velcade in the Phase III ENDEAVOR trial. Flynn sees risk to his Kyprolis $1B sales estimate in a first-line setting, but awaits for additional details from the call and further information regarding another ongoing Phase III trial. He expects Amgen shares to be weak on the news but said the company has additional drivers beyond Kyprolis including Repatha for high cholesterol and Erenumab for migraine with additional data expected in 2H 2016 and Q1 2017. Flynn remains Conviction Buy rated on Amgen and maintains his $206 price target.
09/27/16
PIPR
09/27/16
NO CHANGE
PIPR
Overweight
Amgen's Kyprolis in good shape despite trial miss, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says Amgen's Kyprolis is still likely to be viewed as a "potent backbone, with the right drugs" after a Phase 3 study in front-line myeloma failed to reach its primary endpoint. The analyst believes the impact of the failed trial on Kyprolis use will be limited and he reiterates an Overweight rating on Amgen.
09/29/16
PIPR
09/29/16
NO CHANGE
Target $10
PIPR
Overweight
Arrowhead price target raised to $10 from $8 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals (ARWR) to $10 after the company licensed two preclinical cardiovascular RNAi drugs with Amgen (AMGN). Amgen is the "ideal partner" and Arrowhead's balance sheet is now "meaningfully" strengthened, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Arrowhead.

TODAY'S FREE FLY STORIES

DVN

Devon Energy

$31.17

0.69 (2.26%)

13:30
06/26/17
06/26
13:30
06/26/17
13:30
Options
Devon Energy draws a bullish longer-term option play »

Devon Energy draws a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

DAL

Delta Air Lines

$52.94

0.02 (0.04%)

13:26
06/26/17
06/26
13:26
06/26/17
13:26
Periodicals
Amtrak picks former Delta CEO Anderson as new CEO, WSJ reports »

Former Delta CEO Richard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 30

    Jun

  • 07

    Jul

13:25
06/26/17
06/26
13:25
06/26/17
13:25
General news
Treasury Action: shorter yields dipped slightly after the strong 2-year sale »

Treasury Action: shorter…

PDCE

PDC Energy

$44.72

2.21 (5.20%)

13:22
06/26/17
06/26
13:22
06/26/17
13:22
Hot Stocks
Department of Justice, Colorado file civil complaint against PDC Energy »

The Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

FOXA

21st Century Fox

$27.19

0.22 (0.82%)

13:20
06/26/17
06/26
13:20
06/26/17
13:20
Options
Call buyer opens a notable new position in 20th Century Fox »

Call buyer opens a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$155.07

1.67 (1.09%)

, MSFT

Microsoft

$71.21

0.95 (1.35%)

13:19
06/26/17
06/26
13:19
06/26/17
13:19
Hot Stocks
Facebook, Twitter, Microsoft, YouTube form global forum to counter terrorism »

Facebook (FB), Microsoft…

FB

Facebook

$155.07

1.67 (1.09%)

MSFT

Microsoft

$71.21

0.95 (1.35%)

TWTR

Twitter

$18.35

-0.155 (-0.84%)

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

  • 20

    Jul

$NSD

NASDAQ Market Internals

13:17
06/26/17
06/26
13:17
06/26/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
06/26/17
06/26
13:16
06/26/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$56.22

-0.08 (-0.14%)

, SPY

SPDR S&P 500 ETF Trust

$243.72

0.59 (0.24%)

13:15
06/26/17
06/26
13:15
06/26/17
13:15
Technical Analysis
Technical View: S&P 500 chart view at mid-session »

The small bearish price…

XLK

Technology Select Sector SPDR

$56.22

-0.08 (-0.14%)

SPY

SPDR S&P 500 ETF Trust

$243.72

0.59 (0.24%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GG

Goldcorp

$13.68

-0.12 (-0.87%)

13:15
06/26/17
06/26
13:15
06/26/17
13:15
Options
Goldcorp put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

KR

Kroger

$22.58

-0.02 (-0.09%)

13:15
06/26/17
06/26
13:15
06/26/17
13:15
Hot Stocks
Kroger executive VP Schlotman acquires 2,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
06/26/17
06/26
13:15
06/26/17
13:15
General news
Treasury's $26 B 2-year sale was well received, as expected »

Treasury's $26 B…

DB

Deutsche Bank

$16.89

0.25 (1.50%)

13:12
06/26/17
06/26
13:12
06/26/17
13:12
Periodicals
Deutsche Bank's chief U.S. economist LaVorgna steps down, Bloomberg reports »

Joe LaVorgna, a chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

WDC

Western Digital

$93.34

3.09 (3.42%)

, TOSYY

Toshiba, also use TOSBF

$15.98

-1.415 (-8.14%)

13:11
06/26/17
06/26
13:11
06/26/17
13:11
Periodicals
Toshiba near sale of memory chip unit to consortium, Nikkei reports »

Toshiba (TOSYY) could…

WDC

Western Digital

$93.34

3.09 (3.42%)

TOSYY

Toshiba, also use TOSBF

$15.98

-1.415 (-8.14%)

TOSBF

Toshiba, also use TOSYY

$2.66

-0.22 (-7.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$146.28

0.65 (0.45%)

13:09
06/26/17
06/26
13:09
06/26/17
13:09
Hot Stocks
Apple CEO: 'Inspired' by Indian PM Modi's vision »

Following a meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

ZIXI

ZixCorp

$5.77

-0.06 (-1.03%)

13:05
06/26/17
06/26
13:05
06/26/17
13:05
Hot Stocks
Breaking Hot Stocks news story on ZixCorp »

ETF Managers reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RETA

Reata Pharmaceuticals

$28.97

-0.29 (-0.99%)

12:58
06/26/17
06/26
12:58
06/26/17
12:58
Hot Stocks
Breaking Hot Stocks news story on Reata Pharmaceuticals »

Novo Holdings cuts Reata…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

HSTM

HealthStream

$30.89

0.72 (2.39%)

12:57
06/26/17
06/26
12:57
06/26/17
12:57
Recommendations
HealthStream analyst commentary  »

HealthStream contract end…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

12:55
06/26/17
06/26
12:55
06/26/17
12:55
General news
Treasury 2-year auction preview: the sale should see decent results »

Treasury 2-year auction…

12:55
06/26/17
06/26
12:55
06/26/17
12:55
General news
Breaking General news story  »

San Francisco Federal…

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

12:46
06/26/17
06/26
12:46
06/26/17
12:46
Hot Stocks
Amazon CEO: Excited to keep investing in India »

Following a meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 26

    Jun

  • 28

    Jun

GOOG

Alphabet

$965.59

8.5 (0.89%)

, GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

12:43
06/26/17
06/26
12:43
06/26/17
12:43
Periodicals
EU to likely hit Google with record fine in antitrust case, Reuters says »

EU antitrust authorities…

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

NURO

NeuroMetrix

$2.95

0.06 (2.08%)

12:39
06/26/17
06/26
12:39
06/26/17
12:39
Hot Stocks
NeuroMetrix names Xuan Kong as Chief Data Scientist »

NeuroMetrix provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$17.41

-0.13 (-0.74%)

12:38
06/26/17
06/26
12:38
06/26/17
12:38
Periodicals
Snap taps Internet Association's Woodworth for public policy team, Recode says »

Recode's Tony Romm…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 19

    Jul

DEO

Diageo

$120.05

0.7915 (0.66%)

12:36
06/26/17
06/26
12:36
06/26/17
12:36
Upgrade
Diageo rating change  »

Diageo upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.